F. Tewes, T. F. Bahamondez-canas, and H. D. Smyth, Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02477817

B. Lamy, F. Tewes, D. R. Serrano, I. Lamarche, P. Gobin et al.,

. Marchand, New aerosol formulation to control ciprofloxacin pulmonary concentration, Journal of Controlled Release, vol.271, pp.118-126, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02379277

Q. T. Zhou, S. S. Leung, P. Tang, T. Parumasivam, Z. H. Loh et al., Inhaled formulations and pulmonary drug delivery systems for respiratory infections, Advanced drug delivery reviews, vol.85, pp.83-99, 2015.

H. Stass, J. Nagelschmitz, S. Willmann, H. Delesen, A. Gupta et al., Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study, Clinical drug investigation, vol.33, pp.419-427, 2013.

H. Stass, B. Weimann, J. Nagelschmitz, C. Rolinck-werninghaus, and D. Staab, Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a Phase I, randomized, dose-escalation study, Clinical therapeutics, vol.35, pp.1571-1581, 2013.

A. V. Gontijo, J. Brillault, N. Grégoire, I. Lamarche, P. Gobin et al., Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin, Antimicrobial agents and chemotherapy, vol.58, pp.3942-3949, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02477506

R. Endermann, H. Labischinski, C. Ladel, U. Petersen, and B. Newton, Treatment of bacterial diseases of the respiratory organs, 2011.

M. C. Gaspar, N. Grégoire, J. J. Sousa, A. A. Pais, I. Lamarche et al.,

W. Marchand and . Couet, Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres, European Journal of Pharmaceutical Sciences, vol.93, pp.184-191, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02470904

D. J. Serisier, D. Bilton, A. Soyza, P. J. Thompson, J. Kolbe et al., investigators, Inhaled, dual release liposomal ciprofloxacin in noncystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial, Thorax, pp.812-817, 2013.

S. N. Nurbaeti, J. Brillault, F. Tewes, and J. Olivier, Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols, European Journal of Pharmaceutical Sciences, p.105028, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02477590

D. Cipolla, J. Blanchard, and I. Gonda, Development of liposomal ciprofloxacin to treat lung infections, Pharmaceutics, vol.8, p.6, 2016.

N. G. Türeli, A. Torge, J. Juntke, B. C. Schwarz, N. Schneider-daum et al.,

M. Lehr and . Schneider, Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections, European Journal of Pharmaceutics and Biopharmaceutics, vol.117, pp.363-371, 2017.

P. J. Mcshane, J. G. Weers, T. E. Tarara, A. Haynes, P. Durbha et al., Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination, Pulmonary Pharmacology & Therapeutics, vol.50, pp.72-79, 2018.

F. Tewes, J. Brillault, B. Lamy, P. O'connell, J. C. Olivier et al., Ciprofloxacin-Loaded Inorganic-Organic Composite Microparticles To Treat Bacterial Lung Infection, Molecular pharmaceutics, vol.13, pp.100-112, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01373710

D. C. Griffith, M. N. Dudley, M. W. Surber, K. A. Bostian, and O. Rodny, Aerosol fluoroquinolone formulations for improved pharmacokinetics, in, Patents, 2014.

B. Lamy, D. R. Serrano, P. O'connell, W. Couet, S. Marchand et al., Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation, European Journal of Pharmaceutical Research, vol.1, pp.2-11, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02493122

J. Brillault and F. Tewes, Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones, vol.12, p.387, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02558855

J. Brillault, F. Tewes, W. Couet, and J. Olivier, In vitro biopharmaceutical evaluation of ciprofloxacin/metal cation complexes for pulmonary administration, European Journal of Pharmaceutical Sciences, pp.92-98, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01416565

I. Kukavica-ibrulj and R. Levesque, Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies, Laboratory animals, vol.42, pp.389-412, 2008.

B. G. Torres, R. Awad, S. Marchand, W. Couet, and F. Tewes, In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?, European Journal of Pharmaceutics and Biopharmaceutics, vol.143, pp.35-43, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02477575

A. Bragonzi, D. Worlitzsch, G. B. Pier, P. Timpert, M. Ulrich et al., Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model, Journal of Infectious Diseases, vol.192, pp.410-419, 2005.

E. Growcott, A. Coulthard, R. Amison, E. Hardaker, V. Saxena et al., Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin, Journal of Cystic Fibrosis, vol.10, pp.166-174, 2011.

C. U. Riedel, P. G. Casey, H. Mulcahy, F. O'gara, C. G. Gahan et al., Construction of p16Slux, a novel vector for improved bioluminescent labeling of gram-negative bacteria, Applied and environmental microbiology, vol.73, pp.7092-7095, 2007.

A. D. Brunaugh and H. D. Smyth, Formulation techniques for high dose dry powders, International journal of pharmaceutics, vol.547, pp.489-498, 2018.

D. J. Alexander, C. J. Collins, D. W. Coombs, I. S. Gilkison, C. J. Hardy et al., Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with Pharmaceuticals, Inhalation Toxicology, vol.20, pp.1179-1189, 2008.

P. J. Kuehl, T. L. Anderson, G. Candelaria, B. Gershman, K. Harlin et al.,

J. Holmes, C. Hoppin, J. P. Lackas, H. Norenberg, J. D. Yu et al., Regional particle size dependent deposition of inhaled aerosols in rats and mice, Inhalation Toxicology, pp.27-35, 2012.

S. R. Carvalho, A. B. Watts, J. I. Peters, S. Liu, S. Hengsawas et al.,

I. Williams, Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats, European Journal of Pharmaceutics and Biopharmaceutics, vol.88, pp.136-147, 2014.

J. Weers, Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients, Pulmonary Therapy, 2019.

M. L. Barclay, E. J. Begg, S. T. Chambers, P. E. Thornley, P. K. Pattemore et al., Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.37, pp.1155-1164, 1996.

T. Bjarnsholt, P. Ø. Jensen, M. J. Fiandaca, J. Pedersen, C. R. Hansen et al., Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients, vol.44, pp.547-558, 2009.

N. Høiby, O. Ciofu, and T. Bjarnsholt, Pseudomonas aeruginosa biofilms in cystic fibrosis, Future microbiology, vol.5, pp.1663-1674, 2010.

M. C. Walters, F. Roe, A. Bugnicourt, M. J. Franklin, and P. S. Stewart, Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin, Antimicrobial agents and chemotherapy, vol.47, pp.317-323, 2003.

H. Bandara, D. Nguyen, S. Mogarala, M. Osiñski, and H. Smyth, Magnetic fields suppress Pseudomonas aeruginosa biofilms and enhance ciprofloxacin activity, Biofouling, pp.443-457, 2015.

M. Sønderholm, K. N. Kragh, K. Koren, T. H. Jakobsen, S. E. Darch et al., Pseudomonas aeruginosa Aggregate Formation in an Alginate Bead Model System Exhibits In Vivo-Like Characteristics, p.83, 2017.

D. P. Gnanadhas, M. Elango, A. Datey, and D. Chakravortty, Chronic lung infection by Pseudomonas aeruginosa biofilm is cured by L-Methionine in combination with antibiotic therapy, Scientific reports, vol.5, p.16043, 2015.

P. Meers, M. Neville, V. Malinin, A. Scotto, G. Sardaryan et al., Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections, Journal of Antimicrobial Chemotherapy, pp.859-868, 2008.

H. Cash, D. Woods, B. Mccullough, W. Johanson, and J. Bass, A rat model of chronic respiratory infection with Pseudomonas aeruginosa, American Review of Respiratory Disease, vol.119, pp.453-459, 1979.

K. Lewis, Persister cells, Annual review of microbiology, vol.64, pp.357-372, 2010.

H. Flemming, J. Wingender, U. Szewzyk, P. Steinberg, S. A. Rice et al., Biofilms: an emergent form of bacterial life, Nature Reviews Microbiology, vol.14, p.563, 2016.

N. Q. Balaban, S. Helaine, K. Lewis, M. Ackermann, B. Aldridge et al., Definitions and guidelines for research on antibiotic persistence, Nature Reviews Microbiology, vol.17, pp.441-448, 2019.
URL : https://hal.archives-ouvertes.fr/pasteur-02558489

S. Duncan, L. A. Glover, K. Killham, and J. I. Prosser, Luminescence-based detection of activity of starved and viable but nonculturable bacteria, Appl. Environ. Microbiol, vol.60, pp.1308-1316, 1994.

T. C. Mah and G. A. O'toole, Mechanisms of biofilm resistance to antimicrobial agents, Trends in Microbiology, vol.9, pp.34-39, 2001.

S. Jaffari, B. Forbes, E. Collins, D. J. Barlow, G. P. Martin et al., Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction, International journal of pharmaceutics, vol.447, pp.124-131, 2013.

A. H. De-boer, P. Hagedoorn, E. M. Westerman, P. P. Le-brun, H. G. Heijerman et al.,

. Frijlink, Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses, European journal of pharmaceutical sciences, vol.28, pp.171-178, 2006.